Boston—A review of several late-phase studies of sufentanil sublingual tablets (Dsuvia, AcelRx) concluded that the investigational product is effective and well tolerated for the short-term management of people suffering from moderate to severe acute pain.
“Our goal with this review was to articulate any differences between IV sufentanil and the sublingual sufentanil tablet, identify the patient populations in which the sublingual formulation works best, and note any side effects